Statistics
The Tiziana Life Sciences Ltd stock price is currently $ 0.5699 with a total market cap valuation of $ 72.53M (127.26M shares outstanding). The Tiziana Life Sciences Ltd is trading on NASDAQ under the ticker sign TLSA. Tiziana Life Sciences Ltd price is up
Description
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Company Profile
- Full Name: Tiziana Life Sciences Ltd
- Sector: Healthcare
- Website: https://www.tizianalifesciences.com
